| Oral vitamin D use, by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 2,937 | 32.2% | 9,117 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 3,023 | 35.3% | 8,552 | |
| DOPPS 3(2007) | 2,879 | 37.4% | 7,672 | |
| AusNZ | DOPPS 2(2002) | 248 | 47.9% | 513 |
| DOPPS 3(2006) | 275 | 52.5% | 527 | |
| DOPPS 3(2007) | 300 | 59.4% | 486 | |
| Belgium | DOPPS 2(2002) | 185 | 34.3% | 538 |
| DOPPS 3(2006) | 229 | 44.6% | 509 | |
| DOPPS 3(2007) | 218 | 52.6% | 420 | |
| Canada | DOPPS 2(2002) | 274 | 44.3% | 601 |
| DOPPS 3(2006) | 268 | 48.7% | 551 | |
| DOPPS 3(2007) | 249 | 56.2% | 445 | |
| France | DOPPS 2(2002) | 183 | 34.8% | 528 |
| DOPPS 3(2006) | 194 | 35.4% | 551 | |
| DOPPS 3(2007) | 204 | 38.1% | 543 | |
| Germany | DOPPS 2(2002) | 325 | 57.1% | 571 |
| DOPPS 3(2006) | 367 | 61.9% | 583 | |
| DOPPS 3(2007) | 398 | 62.5% | 623 | |
| Italy | DOPPS 2(2002) | 164 | 28.3% | 576 |
| DOPPS 3(2006) | 213 | 40.1% | 533 | |
| DOPPS 3(2007) | 202 | 37.0% | 542 | |
| Japan | DOPPS 2(2002) | 817 | 45.1% | 1,805 |
| DOPPS 3(2006) | 746 | 40.5% | 1,832 | |
| DOPPS 3(2007) | 762 | 40.6% | 1,867 | |
| Spain | DOPPS 2(2002) | 129 | 21.2% | 613 |
| DOPPS 3(2006) | 129 | 19.5% | 666 | |
| DOPPS 3(2007) | 49 | 9.5% | 555 | |
| Sweden | DOPPS 2(2002) | 286 | 52.3% | 547 |
| DOPPS 3(2006) | 262 | 48.5% | 542 | |
| DOPPS 3(2007) | 245 | 48.4% | 511 | |
| UK | DOPPS 2(2002) | 235 | 42.4% | 565 |
| DOPPS 3(2006) | 243 | 54.4% | 445 | |
| DOPPS 3(2007) | 198 | 57.3% | 351 | |
| US | DOPPS 2(2002) | 91 | 4.1% | 2,260 |
| DOPPS 3(2006) | 97 | 5.7% | 1,813 | |
| DOPPS 3(2007) | 54 | 3.9% | 1,329 | |
| Medications reported as prescribed (not necessarily taken) in previous four months, among all patients |
Please see additional methodological information in the Data Sources and Methods section.